| | | | | | JUGRA (P9-314) Antigen/Virus | JUGRA (P9-314) Antiserum ** |
|---|
| | HI(8u) | CF | PRNT * | CF | PRNT |
|---|
| | Ht/Ho | Ht/Ho | Ht/Ho | Ht/Ho | Ht/Ho |
|---|
|
| | * Expressed as reciprocal of serum dilution showing 50% plaque reduction in Vero cells. | | ** Hyperimmune mouse serum prepared with 5 1P inoculations. | | Batu Cave | 20/160 | 0/32 | 0/320 | 0/64 | 0/400 | | Bukalasa Bat | 20/ND | 0/ND | 0/320 | | 0/400 | | Carey Island | 20/160 | 0/32 | 0/2000 | 16/64 | 0/400 | | Dakar Bat | 40/160 | 0/128 | 25/320 | 8/64 | 0/400 | | Entebbe Bat | 20/320 | 0/16 | 0/ND | 8/64 | | JBE | 20/640 | 0/32 | 15/320 | 0/64 | | Langat | 10/160 | 8/32 | 45/ND | 8/64 | | MML | 0/40 | 0/16 | 0/ND | 0/64 | | Rio Bravo | 40/160 | 0/32 | 15/ND | 8/64 | | Tembusu | 20/320 | 0/32 | 15/>500 | 8/64 |
| | Jugra (P9-314) antigen also was tested by HI, CF, and/or PRNT with antisera for the following group B viruses and shown not to be the same: DEN-1, DEN-2, DEN-3, DEN-4, ILH, MVE, NTA, SLE, SPO, UGS, WSL, WN, YF, and ZIKA. | | |
|